Aclaris Therapeutics (ACRS) revenue breakdown
By segment, Therapeutics Segment is the largest at 86% of fiscal 2024 revenue, growing 61% a year over 5 years.
By product, Licensing is the largest at 76% of fiscal 2025 revenue, growing 54% a year over 5 years.
Revenue by segment
Fiscal years, as Aclaris Therapeutics reports them in its 10-K filings; fiscal 2024 total $19M.
| Segments | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|---|
| Therapeutics Segment | $2M | $696,000 | $932,000 | $25M | $28M | $16M | 86% |
| Contract Research Segment | $13M | $13M | $6M | $4M | $3M | $3M | 14% |
Revenue by product
Fiscal years, as Aclaris Therapeutics reports them in its 10-K filings; fiscal 2025 total $8M.
| Products | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Licensing | — | $690,000 | $809,000 | $25M | $28M | $16M | $6M | 76% |
| Contract research | $5M | $6M | $6M | $4M | $3M | $3M | $2M | 24% |
| Other | $2M | $6,000 | $122,000 | $257,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ACRS.
Open ACRS in InvestinglyQuestions
Where does Aclaris Therapeutics make its money?
In fiscal 2024, by segment: Therapeutics Segment $16M, Contract Research Segment $3M.
From Aclaris Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.